BioSig subsidiary ViralClear adds infectious disease expert Angus Dalgleish to its scientific advisory board

BioSIg Technologies Inc (NASDAQ:BSGM) subsidiary ViralClear Pharmaceuticals Inc announced Thursday that professor Angus Dalgleish has joined its scientific advisory board (SAB). Dalgleish is the foundation chair of oncology and honorary consultant in medical oncology at St. George’s University and Hospital and London as well as principal of the Institute of Cancer Vaccines and Immunotherapy.  “We are delighted to welcome Gus to our Scientific Advisory Board with his breadth of experience in developing antiviral drugs,” said Jerome Zeldis, acting chief medical officer and head of ViralClear. “Gus’ expertise will complement those who are already on the SAB, and we look forward to working with him on this important mission.” READ: BioSig Technologies subsidiary ViralClear adds veteran drug developer to its scientific advisory board Dalgleish is also a fellow of the Royal College of Physicians in both the UK and Australia, in addition to the Royal College of Pathologists and the Academy of Medical Sciences. He has published seminal papers on HIV, its receptor on lymph nodes and its pathogenesis.  “I am delighted to join the SAB of ViralClear Pharmaceuticals with my long-term collaborator, friend and colleague Jerry Zeldis with whom I worked with for several years successfully developing lenalidomide and pomalidomide, and I look forward to repeating this success against COVID-19.” Dalgleish said.  The professor’s addition is the second in as many days for the SAB, which yesterday welcomed drug developer Michael Sofia to its ranks. ViralClear formed the board in July to review its drug discovery and development and counsel the company on its mission to control emerging infections and viral diseases, including the coronavirus (COVID-19). Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com Follow him on Twitter @andrew_kessel